中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2010年
9期
661-665
,共5页
张弘%黄东凤%魏群%华婷琰%李峰%黄介飞
張弘%黃東鳳%魏群%華婷琰%李峰%黃介飛
장홍%황동봉%위군%화정염%리봉%황개비
癌,肝细胞%肝硬化%肿瘤拒绝抗原1
癌,肝細胞%肝硬化%腫瘤拒絕抗原1
암,간세포%간경화%종류거절항원1
Carcinoma,hepatocellular%Liver cirrhosis%Tumor rejective antigen 1
目的 探讨肿瘤拒绝抗原1(TRA1)在肝细胞癌(HCC)和肝硬化组织中的表达水平及其与HCC临床病理学特征的关系.方法 采用RT-PCR法、Western blot和免疫组织化学法分别检测了HCC和肝硬化组织中TRA1 mRNA和蛋白的表达水平,并与HCC临床病理学特征进行相关分析.RT-PCR和Western blot结果采用单因素方差分析;免疫组织化学结果分析采用Fisher's确切概率法;相关性分析采用Spearman等级相关.结果 经对RT-PCR结果分析,HCC和肝硬化组织中TRA1 mRNA表达水平高于正常肝组织水平(F值分别为20.821和12.311,P值均<0.05).Western blot检测结果显示,HCC和肝硬化组织中TRA1蛋白表达水平也高于正常肝组织(F值分别为21.231和20.125,P值均<0.05).经免疫组织化学分析,TRA1蛋白在正常对照组、肝硬化组和HCC组的表达逐渐增强,阳性表达率分别为57.14%、78.95%和93.75%.其表达水平与HCC分化程度呈负相关(r=-0.4655,P<0.01);与HCC患者TNM分期呈正相关(r=0.5157,P<0.01).结论 TRA1在肝硬化和HCC中的过表达可能与肝癌的发生和发展有关,并有可能成为一个潜在的HCC早期诊断标志物;TRA1的检测有助于判断HCC的分化程度,与HBV的感染有一定关系,同时可作为判断预后的指标.
目的 探討腫瘤拒絕抗原1(TRA1)在肝細胞癌(HCC)和肝硬化組織中的錶達水平及其與HCC臨床病理學特徵的關繫.方法 採用RT-PCR法、Western blot和免疫組織化學法分彆檢測瞭HCC和肝硬化組織中TRA1 mRNA和蛋白的錶達水平,併與HCC臨床病理學特徵進行相關分析.RT-PCR和Western blot結果採用單因素方差分析;免疫組織化學結果分析採用Fisher's確切概率法;相關性分析採用Spearman等級相關.結果 經對RT-PCR結果分析,HCC和肝硬化組織中TRA1 mRNA錶達水平高于正常肝組織水平(F值分彆為20.821和12.311,P值均<0.05).Western blot檢測結果顯示,HCC和肝硬化組織中TRA1蛋白錶達水平也高于正常肝組織(F值分彆為21.231和20.125,P值均<0.05).經免疫組織化學分析,TRA1蛋白在正常對照組、肝硬化組和HCC組的錶達逐漸增彊,暘性錶達率分彆為57.14%、78.95%和93.75%.其錶達水平與HCC分化程度呈負相關(r=-0.4655,P<0.01);與HCC患者TNM分期呈正相關(r=0.5157,P<0.01).結論 TRA1在肝硬化和HCC中的過錶達可能與肝癌的髮生和髮展有關,併有可能成為一箇潛在的HCC早期診斷標誌物;TRA1的檢測有助于判斷HCC的分化程度,與HBV的感染有一定關繫,同時可作為判斷預後的指標.
목적 탐토종류거절항원1(TRA1)재간세포암(HCC)화간경화조직중적표체수평급기여HCC림상병이학특정적관계.방법 채용RT-PCR법、Western blot화면역조직화학법분별검측료HCC화간경화조직중TRA1 mRNA화단백적표체수평,병여HCC림상병이학특정진행상관분석.RT-PCR화Western blot결과채용단인소방차분석;면역조직화학결과분석채용Fisher's학절개솔법;상관성분석채용Spearman등급상관.결과 경대RT-PCR결과분석,HCC화간경화조직중TRA1 mRNA표체수평고우정상간조직수평(F치분별위20.821화12.311,P치균<0.05).Western blot검측결과현시,HCC화간경화조직중TRA1단백표체수평야고우정상간조직(F치분별위21.231화20.125,P치균<0.05).경면역조직화학분석,TRA1단백재정상대조조、간경화조화HCC조적표체축점증강,양성표체솔분별위57.14%、78.95%화93.75%.기표체수평여HCC분화정도정부상관(r=-0.4655,P<0.01);여HCC환자TNM분기정정상관(r=0.5157,P<0.01).결론 TRA1재간경화화HCC중적과표체가능여간암적발생화발전유관,병유가능성위일개잠재적HCC조기진단표지물;TRA1적검측유조우판단HCC적분화정도,여HBV적감염유일정관계,동시가작위판단예후적지표.
Objective To investigate the expression of tumor rejective antigen 1 in hepatocellular carcinoma (HCC) and liver cirrhosis(LC) tissues, and the relationship between clinicopathological feature and HCC. Methods The expressions of TRA1 mRNA and its protein were detected by reverse transcription polymerase chain reaction (RT-PCR) and Western blot respectively. Immunohistochemical staining was used to further examine the expression of TRA1 protein in LC, HCC and control tissues. The relationship between clinicopathological feature and HCC was analyzed. Data of RT-PCR and Western blot were analyzed by Oneway ANOVA; results of immunohistochemical staining were analyzed by Fisher's exact test and correlation analysis using Spearman rank correlation. Results RT-PCR data showed that the expression of TRA1 mRNA was higher in HCC and LC tissues than that in the normal liver tissues (F values were 20.821 and 12.311respectively, P < 0.05). The expression of TRA1 protein in HCC and LC tissues was signifcantly higher than that in control by Western blot (F values were 21.231 and 20.125 respectively, P < 0.05). The immunohistochemical data showed the expression of TRA1 protein was gradually increased in HCC group than that in the LC group and control group, and the positive expression rate of TRA1 was 57.14%, 78.95% and 93.75%respectively. The expression of TRA1 protein was negatively correlated with HCC differentiation (r =-0.4655, P = 0.0073) and positively correlated with HCC TNM staging (r = 0.5157, P = 0.0025). Conclusion The over-expression of TRA1 in hepatocirrhosis and HCC is correlated with the formation and development of HCC. It may be a prognostic marker for the diagnosis of HCC and be associated with the degree of differentiation and HBV infection. It can be used as a marker for prognostic prediction of HCC.